Cardiplot

Cardiplot

manidipine

Manufacturer:

Berlin Pharm

Distributor:

Berlin Pharm

Marketer:

Berlin Pharm
Concise Prescribing Info
Contents
Manidipine HCl
Indications/Uses
Mild to moderate essential HTN; HTN w/ renal impairment; severe HTN.
Dosage/Direction for Use
Adult 10-20 mg daily. Recommended starting dose: 10 mg daily. May be increased to 20 mg daily if antihypertensive effect is inadequate after 2-4 wk. Mild hepatic dysfunction Not to exceed 10 mg daily.
Administration
Should be taken with food: Take in the morning after breakfast.
Contraindications
Hypersensitivity to manidipine & other dihydropyridines. Unstable angina or w/in 4 wk of myocardial stroke. Untreated CHF. Severe renal failure (CrCl <10 mL/min). Moderate to severe hepatic failure. Paed.
Special Precautions
Patients w/ left ventricular failure, left ventricular outflow tract obstruction, isolated right heart failure or sick sinus syndrome (w/ no pacemaker); stable coronary disease. Rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption. Hypertensive crisis; hypotension resulting in cerebral infarction. Avoid abrupt w/drawal. Concomitant use w/ CYP3A4 inhibitors eg, antiprotease, cimetidine, ketoconazole, itraconazole, erythromycin, clarithromycin & CYP3A4 inducers eg, phenytoin, carbamazepine, phenobarb, rifampicin; other CYP3A4 substrates eg, terfenadine, astemizole, quinidine & class III antiarrhythmics eg, amiodarone. May affect ability to drive & use machines. Mild to moderate renal dysfunction. Mild hepatic impairment. Reversible biochemical changes in head of spermatozoa which can impair fecundation. Not to be used during pregnancy. Avoid during lactation. Elderly (metabolic processes slow down).
Adverse Reactions
Palpitations, oedema; headache, dizziness, vertigo; hot flushes.
Drug Interactions
Enhanced antihypertensive effect w/ diuretics, β-blockers & other antihypertensive drugs. CYP3A4 inhibitors eg, ketoconazole, itraconazole or CYP3A4 inducers eg, phenytoin, carbamazepine, phenobarb, rifampicin; other CYP3A4 substrates eg, terfenadine, astemizole, quinidine & class III antiarrhythmics (eg, amiodarone). Increased glucoside levels w/ digoxin. Enhanced vasodilatory effect w/ alcohol. Increased systemic bioavailability & hypotensive effect w/ grapefruit juice. Increased antihypertensive effect w/ amifostine. Increased antihypertensive effect & risk of hypotension w/ TCAs/antipsychotics, α-blockers (prazosin, alfuzosin, tamsulosin, terazosin). Potentation of antihypertensive effect w/ baclofen. Reduced antihypertensive effect w/ corticosteroids, tetracosactide.
MIMS Class
Calcium Antagonists
ATC Classification
C08CA11 - manidipine ; Belongs to the class of dihydropyridine derivative selective calcium-channel blockers with mainly vascular effects. Used in the treatment of cardiovascular diseases.
Presentation/Packing
Form
Cardiplot tab 10 mg
Packing/Price
10 × 10's
Form
Cardiplot tab 20 mg
Packing/Price
10 × 10's;50 × 10's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in